NRG-LU004

Phase I Trial of Radiotherapy Combined with Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

Principal Investigator

Steven Lin, MD PhD

Status

Disease Site

Lung [LU] Non-small Cell Lung Cancer

Phase

I

Developmental Therapeutics

No

Primary Objective

To evaluate if the addition of MEDI4736 (durvalumab) to two schedules of radiation therapies (60 Gy in 30 fractions or 60 Gy in 15 fractions) is safe.

Patient Population

Unresectable or inoperable, non-metastatic stage II-III Non-Small Cell Lung Cancer patients who have PD-L1 high expressing tumors (>=50%) within 60 days prior to registration.

Target Accrual

24